Cargando…

Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Detalles Bibliográficos
Autores principales:	Suzuki, Rikio, Hidehsima, Teru, Mimura, Naoya, Minami, Jiro, Ohguchi, Hiroto, Kikuchi, Shohei, Yoshida, Yasuhiro, Gorgun, Gullu, Cirstea, Diana, Cottini, Francesca, Jakubikova, Jana, Tai, Yu-Tzu, Chauhan, Dharminder, Richardson, Paul G., Munshi, Nikhil, Utsugi, Teruhiro, Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318711/ https://www.ncbi.nlm.nih.gov/pubmed/25306900 http://dx.doi.org/10.1038/leu.2014.300

Ejemplares similares

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
por: Suzuki, Rikio, et al.
Publicado: (2015)

Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
por: Cirstea, Diana, et al.
Publicado: (2013)

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
por: Hideshima, T, et al.
Publicado: (2015)

The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival
por: Ohguchi, Hiroto, et al.
Publicado: (2016)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

In vitro Antitumor Activity of TAS‐103, a Novel Quinoline Derivative That Targets Topoisomerases I and II
por: Aoyagi, Yoshimi, et al.
Publicado: (1999)

A Dual Topoisomerase Inhibitor, TAS‐103, Induces Apoptosis in Human Cancer Cells
por: Ohyama, Tomoko, et al.
Publicado: (1999)

Antitumor Activity of a Novel Quinoline Derivative, TAS‐103, with Inhibitory Effects on Topoisomerases I and II
por: Utsugi, Teruhiro, et al.
Publicado: (1997)

Establishment and Characterization of 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐c]quinolin‐7‐one dihydrochloride (TAS‐103)‐resistant Cell Lines
por: Aoyagi, Yoshimi, et al.
Publicado: (2000)

Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice
por: Solopov, Pavel A., et al.
Publicado: (2022)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2021)

New Challenges and Inspired Answers for Anticancer Drug Discovery and Development
por: Utsugi, Teruhiro
Publicado: (2013)

TAS-116, a Well-Tolerated Hsp90 Inhibitor, Prevents the Activation of the NLRP3 Inflammasome in Human Retinal Pigment Epithelial Cells
por: Ranta-aho, Sofia, et al.
Publicado: (2021)

TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice
por: Tanaka, Yuki, et al.
Publicado: (2020)

Author Correction: TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice
por: Tanaka, Yuki, et al.
Publicado: (2022)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
por: Ohguchi, Hiroto, et al.
Publicado: (2017)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

TAS‐116 (pimitespib), a heat shock protein 90 inhibitor, shows efficacy in preclinical models of adult T‐cell leukemia
por: Ikebe, Emi, et al.
Publicado: (2021)

Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?
por: Ohguchi, Yasuyo, et al.
Publicado: (2022)

DIS3: The Enigmatic Gene in Multiple Myeloma
por: Ohguchi, Yasuyo, et al.
Publicado: (2023)

Shieldings: TAS
Publicado: (2004)

Shieldings: TAS
Publicado: (2004)

Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells
por: Muguruma, Yukari, et al.
Publicado: (2017)

Vanillin Activates Human Bitter Taste Receptors TAS2R14, TAS2R20, and TAS2R39
por: Morini, Gabriella, et al.
Publicado: (2021)

Tas chebal : jun chajp a'tel pajbil /
por: González Dillon, Mónica
Publicado: (2013)

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
por: HIDESHIMA, HIROMASA, et al.
Publicado: (2014)

Energy Deposition in the Triplet and TAS Issues
por: Broggi, F
Publicado: (2008)

Implementation of TasP: challenges and opportunities
por: Lange, Joep
Publicado: (2014)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Tunable Contact Types and Interfacial Electronic Properties in TaS(2)/MoS(2) and TaS(2)/WSe(2) Heterostructures
por: Zhu, Xiangjiu, et al.
Publicado: (2023)

Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition
por: Nagai, Nao, et al.
Publicado: (2018)

Members of Bitter Taste Receptor Cluster Tas2r143/Tas2r135/Tas2r126 Are Expressed in the Epithelium of Murine Airways and Other Non-gustatory Tissues
por: Liu, Shuya, et al.
Publicado: (2017)

Enhanced superconductivity in atomically thin TaS(2)
por: Navarro-Moratalla, Efrén, et al.
Publicado: (2016)

Raman Optical Activity of 1T-TaS(2)
por: Lacinska, Ewa M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sen02fckpu5htsiasik6pjtnbm